Low-dose transdermal estradiol for vasomotor symptoms: A systematic review

Menopause

Volumn 22, Issue 1, 2015, Pages 114-121

  Corbelli, Jennifer ^a   Shaikh, Nader ^b   Wessel, Charles ^b   Hess, Rachel ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Hormone therapy; Low dose; Systematic review; Transdermal; Vasomotor

Indexed keywords

ESTRADIOL; GESTAGEN; PLACEBO;

DRUG EFFICACY; DRUG FORMULATION; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; DOUBLE BLIND PROCEDURE; HOT FLASHES; INTRADERMAL DRUG ADMINISTRATION; MEDLINE; STATISTICAL BIAS;

ADMINISTRATION, CUTANEOUS; BIAS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MEDLINE; PLACEBOS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920280023     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000258     Document Type: Review

References (48)

1. Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Ockene JK, Barad DH, Cochrane BB, et al Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
3. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
4. Kim N, Gross C, Curtis J, et al The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J Gen Intern Med 2005;20:1026-1031.
5. Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005;14:171-176.
6. Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005;14:837-842.
7. Buist DS, Newton KM, Miglioretti DL, et al Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
8. Parente L, Uyehara C, Larsen W, Whitcomb B, Farley J. Long-term impact of the Women's Health Initiative on HRT. Arch Gynecol Obstet 2008;277:219-224.
9. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012;19:616-621.
10. Ettinger B, Wang SM, Leslie RS, et al Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012;19:610-615.
11. Canonico M, Scarabin PY. Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms. Menopause 2011;18:1038-1039.
12. Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052-1059.
13. Chetkowski RJ, Meldrum DR, Steingold KA, et al Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620.
14. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004;7:347-356.
15. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118(suppl 12B):74-78.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
17. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006;94:41-47.
18. Haynes RB, Kastner M, Wilczynski NL, Hedges T. Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. BMC Med Inform Decis Mak 2005;5:8.
19. Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric 2001; 4:110-119.
20. Kaunitz AM. Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts. Menopause 2012;19:602-603.
21. The North American Menopause Society. Menopause Practice: A Clinician's Guide. 4th ed. Mayfield Heights, OH: The North American Menopause Society; 2010.
22. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley and Sons; 2008.
23. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17A-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779.
24. Buster JE, Koltun WD, Pascual ML, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:1343-1351.
25. Cohen L, Coxwell WL, Melchione T, et al. Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausalwomen. Curr Ther Res Clin E 1999;60:534-547.
26. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2009;16:132-140.
27. Rovati LC, Setnikar I, Genazzani AR. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Gynecol Endocrinol 2000;14:282-291.
28. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195-207.
29. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109:588-596.
30. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587-592.
31. Utian WH, Burry KA, Archer DF, et al Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181:71-79.
32. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202.
33. Utian WH, Archer DF, Bachmann GA, et al Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
34. Center for Drug Evaluation and Research. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2003.
35. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142:1003-1013.
36. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31.
37. Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause 2002;9:137-144.
38. Stefanick ML, Anderson GL, Margolis KL, et al Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295: 1647-1657.
39. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779-787.
40. Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009:CD000402.
41. Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P. Longterm safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014;121:700-705.
42. Prescribing information MenostarA (estradiol transdermal system). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/020375s023LBL.pdf. Accessed January 8, 2014.
43. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087.
44. Utian WH, Schiff I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48.
45. Fraser IS,Mansour D. Delivery systems for hormone replacement therapy. Expert Opin Drug Deliv 2006;3:191-204.
46. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228.
47. Holst J, Backstrom T, Hammarback S, von Schoultz B. Progestogen addition during oestrogen replacement therapyVeffects on vasomotor symptoms and mood. Maturitas 1989;11:13-20.
48. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13-18.